“The Prospective Randomized Trial Evaluating the Efficacy of the Mitomycin C and Cisplatin Regimen (MP) versus Standard First-Line Chemotherapy in Patients With Advanced BRCA1 2-Associated Ovarian Cancer (NCT04747717)”. 2022. Voprosy Onkologii 68 (5): 628-38. https://doi.org/10.37469/0507-3758-2022-68-5-628-638.